METTL3 regulates breast cancer-associated alternative splicing switches
Cyrinne Achour, Devi Prasad Bhattarai, P Groza, Ángel Román, Francesca Aguiló
Abstract
Abstract Alternative splicing (AS) enables differential inclusion of exons from a given transcript, thereby contributing to the transcriptome and proteome diversity. Aberrant AS patterns play major roles in the development of different pathologies, including breast cancer. N 6 -methyladenosine (m 6 A), the most abundant internal modification of eukaryotic mRNA, influences tumor progression and metastasis of breast cancer, and it has been recently linked to AS regulation. Here, we identify a specific AS signature associated with breast tumorigenesis in vitro. We characterize for the first time the role of METTL3 in modulating breast cancer-associated AS programs, expanding the role of the m 6 A-methyltransferase in tumorigenesis. Specifically, we find that both m 6 A deposition in splice site boundaries and in splicing and transcription factor transcripts, such as MYC , direct AS switches of specific breast cancer-associated transcripts. Finally, we show that five of the AS events validated in vitro are associated with a poor overall survival rate for patients with breast cancer, suggesting the use of these AS events as a novel potential prognostic biomarker.